Stocktoria
Celularity Inc CELU
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-05-23
Celularity Inc statistics & valuation
Market cap$17.9M
P / S0.7×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | — | 29.7% | -9.4% | 54.8% |
| Operating margin | -230.9% | -70.7% | -844.4% | -142.4% | -511.2% |
| Net margin | -345.4% | -106.8% | -862.0% | 79.0% | -469.3% |
| FCF margin | — | -12.1% | -174.5% | -796.2% | -545.1% |
| Return on assets | -85.5% | -43.6% | -136.4% | 3.5% | -24.2% |
| Return on equity | 241.0% | -655.1% | -479.2% | 7.1% | -100.7% |
| Current ratio | 0.15 | 0.38 | 0.29 | 0.54 | 2.25 |
| Revenue growth | -51.0% | 138.1% | 26.7% | -15.7% | 49.4% |
Source: SEC EDGAR filings · CIK 0001752828 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.